Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.76EUR
10:44am EDT
Change (% chg)

€-0.02 (-2.56%)
Prev Close
€0.78
Open
€0.76
Day's High
€0.78
Day's Low
€0.76
Volume
310,608
Avg. Vol
452,208
52-wk High
€1.56
52-wk Low
€0.64

ALNEV.PA

Chart for ALNEV.PA

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.72
Market Cap(Mil.): €33.51
Shares Outstanding(Mil.): 42.97
Dividend: --
Yield (%): --

Financials

  ALNEV.PA Industry Sector
P/E (TTM): -- 43.70 36.51
EPS (TTM): -0.19 -- --
ROI: -63.66 -0.32 13.85
ROE: -102.41 -3.00 14.77

BRIEF-Stellar Biotechnologies, Neovacs announce formation of new company Neostell S.A.S. in France

* Stellar Biotechnologies and Neovacs announce formation of new company Neostell S.A.S. In France

Jul 19 2016

BRIEF-Neovacs and Stellar Biotechnologies launch Neostell, joint venture to manufacture Kinoids

* Neovacs and Stellar Biotechnologies announce launch of Neostell, joint venture to manufacture Kinoids

Jul 19 2016

BRIEF-Neovacs raises 8 million euros in capital increase

* Said on Wednesday it raised 8 million euros ($9.1 million) in capital increase

Jun 23 2016

BRIEF-Neovacs receives positive opinion from European Authorities for the clinical phase IIA study in dermatomyositis

* Receives positive opinion from European Authorities for the clinical phase IIA study in dermatomyositis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 06 2016

BRIEF-Neovacs launches capital increase of 8 million euros

* Launches a capital increase of 8 million euros ($8.90 million) with preferential subscription rights

Jun 01 2016

BRIEF-Neovacs and Stellar Biotechnologies sign JV agreement to create Neostell

* Neovacs and Stellar Biotechnologies sign joint venture agreement to create Neostell

May 12 2016

BRIEF-Stellar Biotechnologies and Neovacs sign JV

* Stellar Biotechnologies and Neovacs sign joint venture agreement to manufacture conjugated therapeutic vaccines with Stellar Klh(TM)

May 11 2016

BRIEF-Neovacs obtains FDA approval to extend its phase IIb clinical trial in Lupus to United States

* Obtains FDA approval to extend its phase IIb clinical trial in Lupus to United States Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 28 2016

BRIEF-Neovacs gets approval of South Korean healthcare regulator for Phase IIb trial with Lupus

* Gets approval of South Korean healthcare regulator for Phase IIb trial with Lupus Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 14 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Wright Reports
$75.00
Provider : Reuters Investment Profile
$20.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.